Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399658 · ClinicalTrials.gov registry record · Phase 2
Image-Guided Gynecologic Brachytherapy
A Phase 2 study of Cervical Cancer and Uterine Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT01399658 is a Phase 2 study of Cervical Cancer and Uterine Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 93 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01399658, a Phase 2 study of Cervical Cancer and Uterine Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
Conditions Studied
Interventions
- PROCEDURE Image-guided brachytherapy
- DRUG 3'-Deoxy-3'-18f-Fluorothymidine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399658
The ClinicalTrials.gov registry entry for NCT01399658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Image-guided brachytherapy is the first listed.
NCT01399658 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01399658 about?
NCT01399658 is a clinical study titled "Image-Guided Gynecologic Brachytherapy". Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the...
What is the current status of trial NCT01399658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2011-09. Estimated completion is 2016-06.
What conditions does trial NCT01399658 study?
This clinical trial studies the following conditions: Cervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva.
What interventions are being tested in trial NCT01399658?
The interventions under investigation include: Image-guided brachytherapy (PROCEDURE), 3'-Deoxy-3'-18f-Fluorothymidine (DRUG).
Who is sponsoring clinical trial NCT01399658?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01399658 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.